Vanguard PRIMECAP Fund Admiral Shares

This large- and mid-capitalization growth fund is managed with a long-term perspective, extremely low turnover, and a well-established investment strategy. Since the fund’s inception in 1984, PRIMECAP Management Company, the advisor, has followed an approach in which multiple portfolio managers independently manage a portion of the fund, which provides diversification of thought. One risk to note is that the fund may become concentrated in a few sectors, notably technology and health care. Short-term performance may be volatile when these sectors are strongly in or out of favor. This fund may be considered a complement to an already diversified portfolio with a long-term time horizon.

Vanguard PRIMECAP Fund Admiral Shares trades as VPMAX on NASDAQ. The company is classified in Financial Services / Asset Management and reports in USD.

The current profile places the business in Asset Management. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Vanguard PRIMECAP Fund Admiral Shares can be compared against peers such as iShares Core S&P Total U.S. Stock Market ETF, Invesco S&P 500 Equal Weight ETF, Schwab U.S. Dividend Equity ETF, Vanguard FTSE All-World ex-US ETF, Vanguard FTSE All-World ex-US Index Fund Admiral Shares, Vanguard High Dividend Yield Index Fund Admiral Shares.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $78.61B, beta of 1.09, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

VPMAX currently shows total debt of N/A and beta of 1.09. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: N-CSRS (2026-06-01 00:00:00), N-CSRS (2026-06-01 00:00:00), NPORT-P (2026-05-28 00:00:00), NPORT-P (2026-05-28 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://investor.vanguard.com/investment-products/mutual-funds/profile/vpmax

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.